Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10

被引:18
作者
Creery, D
Angel, JB
Aucoin, S
Weiss, W
Cameron, WD
Diaz-Mitoma, F
Kumar, A
机构
[1] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada
[2] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada
[3] Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada
[4] Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada
关键词
D O I
10.1128/CDLI.9.6.1212-1221.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the expression of membrane-bound CD14 (mCD14) on monocytes and soluble CD14 (sCD14) released into the culture supernatants of peripheral blood lymphocytes (PBMC) from human immunodeficiency virus (HIV)-infected individuals. Monocytes from HIV-positive individuals exhibited both enhanced mCD14 expression and sCD14 production in the PBMC culture supernatants compared to the levels of mCD14 and sCD14 in HIV-negative individuals. This enhanced mCD14 expression and sCD14 production in HIV-infected individuals may be due to the effects of cytokines, the bacterial product lipopolysaccharide (LPS), and/or the HTV regulatory antigens Tat and Net Interleukin-10 (IL-10), an immunoregulatory cytokine, as well as LPS enhanced mCD14 expression and the release of sCD14 in the culture supernatants. HIV-Nef, unlike Tat, enhanced mCD14 expression on monocytes but did not induce the release of sCD14 into the culture supernatants. Studies conducted to investigate the mechanism underlying HIV-Nef-induced mCD14 expression revealed that HIV-Nef upregulated mCD14 expression via a mechanism that does not involve endogenously produced IL-10. In contrast, LPS upregulated the expression of mCD14 and increased the release of sCD14 via a mechanism that involves, at least in part, endogenously produced IL-10. Furthermore, dexamethasone, an anti-inflammatory and immunosuppressive agent, inhibited HIV-Nef-induced CD14 expression in an IL-10-independent manner. In contrast, dexamethasone inhibited IL-10-dependent LPS-induced CD14 expression by interfering with IL-10-induced signals but not by blocking IL-10 production. These results suggest that HIV-Nef and IL-10 constitute biologically important modulators of CD14 expression which may influence immunobiological responses to bacterial infections in HIV disease.
引用
收藏
页码:1212 / 1221
页数:10
相关论文
共 58 条
[1]  
AKRIDGE RE, 1994, J IMMUNOL, V153, P5782
[2]  
AMEISEN JC, 1989, NEW ENGL J MED, V320, P251
[3]  
ANGEL JB, 1995, J INTERF CYTOK RES, V15, P575
[4]   CD14 IS INVOLVED IN CONTROL OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 EXPRESSION IN LATENTLY INFECTED-CELLS BY LIPOPOLYSACCHARIDE [J].
BAGASRA, O ;
WRIGHT, SD ;
SESHAMMA, T ;
OAKES, JW ;
POMERANTZ, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (14) :6285-6289
[5]   Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway [J].
Brigino, E ;
Haraguchi, S ;
Koutsonikolis, A ;
Cianciolo, GJ ;
Owens, U ;
Good, RA ;
Day, NK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3178-3182
[6]  
BRINKMANN V, 1995, J IMMUNOL, V155, P3322
[7]  
CalzadaWack JC, 1996, J INFLAMM, V46, P78
[8]   IL-4 and CD40 ligation affect differently the differentiation, maturation, and function of human CD34+ cell-derived CD1a+CD14- and CD1a-CD14+ dendritic cell precursors in vitro [J].
Canque, B ;
Camus, S ;
Yagello, M ;
Gluckman, JC .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (02) :235-244
[9]   THE TH1-TH2 HYPOTHESIS OF HIV-INFECTION - NEW INSIGHTS [J].
CLERICI, M ;
SHEARER, GM .
IMMUNOLOGY TODAY, 1994, 15 (12) :575-581
[10]   ROLE OF INTERLEUKIN-10 IN T-HELPER CELL DYSFUNCTION IN ASYMPTOMATIC INDIVIDUALS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].
CLERICI, M ;
WYNN, TA ;
BERZOFSKY, JA ;
BLATT, SP ;
HENDRIX, CW ;
SHER, A ;
COFFMAN, RL ;
SHEARER, GM .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :768-775